ResMed Dismisses KPMG as Auditor, Appoints PwC in Competitive Review
The $32 billion medical device maker has replaced its longtime auditor and announced Carol Burt will succeed Ron Taylor as lead director after more than two decades of board service.
Auditor Change Follows Comprehensive Review
ResMed Inc. (NYSE: RMD) has dismissed KPMG LLP as its independent auditor and appointed PricewaterhouseCoopers LLP to fill the role, according to an 8-K filing dated August 17, 2026. The San Diego-based sleep and respiratory care technology company disclosed that its audit committee completed a "competitive review process" before approving the change on August 13, 2026 (8-K filing, 2026-08-17).
KPMG had served as ResMed's principal accountant through the fiscal years ended June 30, 2026 and 2025. The firm's reports on those consolidated financial statements "did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles" (8-K filing, 2026-08-17).
The filing emphasized there were no disagreements with KPMG "on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures" during the relevant period (8-K filing, 2026-08-17). KPMG confirmed its agreement with ResMed's statements in a letter to the Securities and Exchange Commission included in the filing.
PwC's appointment is subject to completion of the firm's standard client acceptance procedures and will be effective for the fiscal year ending June 30, 2027 (8-K filing, 2026-08-17).
Board Leadership Transition
Concurrent with the auditor change, ResMed announced a significant board transition. Ron Taylor, who has served as a director for more than 21 years and as lead director since 2013, will not stand for reelection at the company's annual meeting scheduled for November 18, 2026 (8-K filing, 2026-08-17).
Carol Burt will succeed Taylor as lead director effective November 15, 2026. Burt has been a ResMed board member since 2013 and currently chairs the Nominating and Governance Committee while serving on the Audit Committee and the Compliance, Privacy and Quality Committee (8-K filing, 2026-08-17).
Chairman and CEO Mick Farrell praised both directors in a press release, calling Burt "an outstanding leader with deep governance experience" and crediting Taylor with helping "guide the company's governance, strategy and long-term growth" during a period of significant transformation (8-K filing, 2026-08-17).
Taylor's retirement is "not due to any disagreement with Resmed on any matter relating to Resmed's operations, policies or practices," according to the filing (8-K filing, 2026-08-17).
Context
ResMed, which develops digital health solutions and cloud-connected devices for sleep and respiratory care, operates in 140 countries. The company has a market capitalization of approximately $32 billion, with shares last closing at $224.46.
According to MarginX data, the company is scheduled to pay a $0.66 cash dividend on August 20, 2026, and is expected to report first-quarter fiscal 2027 results on October 29, 2026. Recent insider activity shows CEO Farrell exercising options and selling 4,991 shares.
This article was generated by MarginX from the 8-K filing on 2026-08-17. It is not investment advice.